Enhancing Patient Understanding of Medication Risks and Benefits

被引:5
|
作者
Blalock, Susan J. [1 ]
Solow, Elizabeth B. [2 ]
Reyna, Valerie F. [3 ]
Keebler, Molly [4 ]
Carpenter, Delesha [1 ]
Hunt, Caprice [1 ]
Hickey, Genevieve [1 ]
Curtis, Jeffrey R. [5 ]
O'Neill, Kimberlee [1 ]
Chapman, Sandra Bond [4 ]
机构
[1] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA
[2] Univ Texas Southwestern, Dallas, TX USA
[3] Cornell Univ, Ithaca, NY USA
[4] Univ Texas Dallas, Dallas, TX USA
[5] Univ Alabama Birmingham, Birmingham, AL USA
关键词
DRUG FACTS BOX; RHEUMATOID-ARTHRITIS PATIENTS; FORMAL JOINT COUNTS; DISEASE-ACTIVITY; DECISION; LITERACY; HARMS; CARE; INFORMATION; KNOWLEDGE;
D O I
10.1002/acr.24421
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate the effectiveness of 2 interventions, including the DrugFactsBox format for presenting written medication information and the SMART (Strategic Memory Advanced Reasoning Training) program designed to enhance gist (i.e., "bottom-line" meaning) reasoning ability. Methods We used a 2 x 2 factorial research design. A total of 286 patients with rheumatoid arthritis were randomly assigned to 1 of 4 groups, including DrugFactsBox with the SMART program, DrugFactsBox without the SMART program, other consumer medication information (CMI) with the SMART program, and other CMI without the SMART program. Data were collected via telephone interviews and online questionnaires at 4 time points, including baseline and 6-week, 3-month, and 6-month time points following baseline. The primary outcome variable was informed decision-making, which was defined as making a value-consistent decision concerning use of disease-modifying antirheumatic drugs based on adequate knowledge. Results We found no main effects for the 2 interventions, either alone or in combination. However, there was a significant interaction between assignment to the SMART/no SMART groups and informed decision-making at baseline. Among participants in the SMART groups who did not meet the criteria for informed decision-making at baseline, 42.5% met the criteria at the 6-month follow-up, compared to 23.6% of participants in the no SMART groups (mean difference 18.9 [95% confidence interval 5.6, 32.2]; P = 0.007). This difference was driven by increased knowledge in the SMART groups. Among participants who met the criteria for informed decision-making at baseline, the difference between the SMART and no SMART groups was not statistically significant. Conclusion Participation in a theory-driven program to enhance gist reasoning may have a beneficial effect on informed decision-making among patients with inadequate knowledge concerning therapeutic options.
引用
收藏
页码:142 / 150
页数:9
相关论文
共 50 条
  • [41] The Subjective Understanding of Guideline Recommendations and of the Risks of the Side Effects of Medication
    Betsch, Tilmann
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2013, 110 (40): : 661 - 662
  • [42] Understanding fetal risks of antihypertensive medication use during pregnancy
    Cooper, William O.
    Caton, Alissa R.
    van den Berg, Lolkje T. W. de Jong
    Mitchell, Allen A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S210 - S211
  • [43] Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity
    Caughey, Gillian E.
    Tait, Kirsty
    Vitry, Agnes I.
    Shakib, Sepehr
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 131 - 140
  • [44] Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease
    Chang Hwan Pang
    Won-Sang Cho
    Hyun-Seung Kang
    Jeong Eun Kim
    Scientific Reports, 11
  • [45] Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery
    Katz, J
    Feldman, MA
    Bass, EB
    Lubomski, LH
    Tielsch, JM
    Petty, BG
    Fleisher, LA
    Schein, OD
    OPHTHALMOLOGY, 2003, 110 (09) : 1784 - 1788
  • [46] Balancing the risks and benefits of medication organizers: reply to Wang etal.
    Davis, Seth
    Wang, Josh
    Villeneuve, Eric
    Persson, Megan
    Amiel, Jacques-Alexandre
    Gosselin, Sophie
    CLINICAL TOXICOLOGY, 2018, 56 (02) : 155 - 155
  • [47] Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease
    Pang, Chang Hwan
    Cho, Won-Sang
    Kang, Hyun-Seung
    Kim, Jeong Eun
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [49] Heterogeneity of patient preferences for benefits and risks of antiplatelet therapies
    Pinto, Cathy Anne
    Chua, Gin Nie
    Brookes, Ella
    Hyacinthe, Johanna
    Tervonen, Tommi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 8 - 8
  • [50] Is understanding of the risks and benefits of radiotherapy affected by the consenting healthcare professional?
    Wolfson, P.
    Carter, T.
    Kudhail, J.
    Reynolds, T.
    Moule, R.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S921 - S921